Canaccord Genuity Starts BioXcel Therapeutics (BTAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Price: $0.07 --0%
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
7 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
Canaccord Genuity initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $21.00.
For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.
Shares of BioXcel Therapeutics closed at $10.24 Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- StoneX Starts SoFi Technologies (SOFI) at Buy
- Morgan Stanley Starts CVC Capital Partners plc (CVC:NA) at Overweight
- Barclays Starts Quintiles (Q) at Overweight
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
